Yuekang Pharmaceutical: Subsidiary YKYY033 injection has obtained clinical trial approval from the US FDA.

Yuekang Pharmaceuticals announced that its subsidiary, Beijing Yuekang Kecyue Medical Technology Co., Ltd., has recently received a letter from the U.S. FDA approving the clinical trial application for YKYY033 injection for the prevention and treatment of venous and arterial thrombosis, with IND number 181821. This drug is an independently developed chemically synthesized double-strand siRNA medication, and preclinical studies have shown significant anti-thrombotic efficacy without increasing the risk of bleeding. This product has received approval for multiple anticoagulant-related clinical trial indications from the National Medical Products Administration in June and July 2026.